You are here: Industry Insights > ADC

News List

Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
MSD, BI and CStone Pharmaceuticals Made Significant Investments in ROR1 ADC Far-away from the Crowd
May 06, 2024
Ipsen Invested USD 900 Million to Introduce Sutro Biopharma ADC.
2024 Medical Breakthroughs: New Hope to Patients Shruti Talashi
April 11, 2024
The pharmaceutical industry is set for a major shake-up in 2024.
Advancements in scientific technologies to Drug discovery and Development 2023 Shruti Talashi
January 02, 2024
Technological advancement apart from a deeper comprehension of disease biology, and an emphasis on breaking down conventional boundaries is driving this era of profound change in the drug development industry.
A comprehensive review of the currently marketed ADC drugs: the industry maintains high prosperity WND
November 07, 2023
Antibody-drug conjugates (ADCs) are a class of drugs composed of antibodies targeting tumor antigens and a variable number of small molecule toxins linked through connectors.
PD-1 Inhibitor Combined with ADC, the Strong Cooperation of Innovent and Remegen Far-away from the Crowd/PharmaSources
July 25, 2023
Recently, Innovent and Remegen will carry out a clinical research cooperation on the combination of Sintilimab Injection, a PD-1 inhibitor, with RC88, a novel antibody-drug conjugate targeting MSLN, and RC108, a novel ADC targeting c-MET, res.
More ADCs made in China, Led by Kelun Pharmaceutical, Expanding into the World Market with a Total Transaction Amount of over USD 20 billion Yi/PharmaSources
June 06, 2023
More ADCs made in China, led by Kelun Pharmaceutical, expanding into the world market with a total transaction amount of over USD 20 billion.
Competitive Landscape of the New Drug Target Nectin-4 in China Yefenghong/PharmaSources
May 22, 2023
Araris Biotech AG announced on April 17 that it will acquire ARS Pharmaceutical's Nectin-4 antibody. Araris Biotech intends to use the acquired Nectin-4 antibody to develop differentiated Nectin-4 ADCs using its proprietary linker technology.
The Increasing ADC+CDMO Industry Collaboration Yefenghong/PharmaSources
April 19, 2023
Recently, the heat on ADC pipeline deals is around, and the deal sizes are kept refreshing.
Monthly News Review of PharmaSources (February) - Business Caicai/PharmaSources
March 14, 2023
On the business, Keymed Biosciences Inc. and Lepu Biopharma jointly announced an exclusive global licensing agreement with AstraZeneca for CMG901. In terms of the listing, Kelun Pharmaceutical's subsidiary Kelun Biotech intends to go public in Hong Kong.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page